Literature DB >> 21890829

Recurrence and outcomes of Stevens-Johnson syndrome and toxic epidermal necrolysis in children.

Yaron Finkelstein1, Gordon S Soon, Patrick Acuna, Mathew George, Elena Pope, Shinya Ito, Neil H Shear, Gideon Koren, Michael W Shannon, Facundo Garcia-Bournissen.   

Abstract

OBJECTIVES: To report clinical course, etiology, management, and long-term outcomes of children suffering from Stevens-Johnson syndrome (SJS) or toxic epidermal necrolysis (TEN).
METHODS: We conducted a study of all pediatric patients with SJS or TEN admitted between 2000 and 2007 to the Hospital for Sick Children and Children's Hospital Boston, and particular attention was paid to clinical manifestations, etiology, mortality, and long-term outcomes.
RESULTS: We identified 55 cases of SJS (n = 47), TEN (n = 5), or SJS/TEN overlap syndrome (n = 3). Drugs were identified as the most likely etiologic agent in 29 children (53%); antiepileptic drugs were the most common agents (n = 16), followed by sulfonamide antibiotics (n = 7) and chemotherapy drugs (n = 2). Acute Mycoplasma pneumoniae infection was confirmed in 12 children (22%), and herpes simplex virus was confirmed in 5 children (9%). Treatment regimens differed significantly between participating sites and included systemic antimicrobial agents (67%), systemic corticosteroids (40%), and antiviral drugs (31%). Intravenous immunoglobulin was administered to 21 children (38%), of whom 8 received concomitant systemic corticosteroids. Ten children (18%) had recurrence of SJS up to 7 years after the index episode, and 3 experienced multiple recurrences. Twenty-six children (47%) suffered long-term sequelae that mostly involved the skin and eyes.
CONCLUSIONS: Mortality rate in children was lower than that reported in adults, but half of affected children suffered long-term complications. The recurrence rate of SJS was high (1 in 5), which suggests vulnerability and potential genetic predisposition. In the absence of standardized management guidelines for these conditions, treatment regimens differed significantly between participating institutions.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21890829     DOI: 10.1542/peds.2010-3322

Source DB:  PubMed          Journal:  Pediatrics        ISSN: 0031-4005            Impact factor:   7.124


  32 in total

1.  A Retrospective Cohort Study of the Management and Outcomes of Children Hospitalized with Stevens-Johnson Syndrome or Toxic Epidermal Necrolysis.

Authors:  James W Antoon; Jennifer L Goldman; Samir S Shah; Brian Lee
Journal:  J Allergy Clin Immunol Pract       Date:  2018-05-30

2.  Evaluation of the patients diagnosed with Stevens Johnson syndrome and toxic epidermal necrolysis: a single center experience.

Authors:  Şükrü Çekiç; Yakup Canıtez; Nihat Sapan
Journal:  Turk Pediatri Ars       Date:  2016-09-01

3.  Pediatric Stevens-Johnson syndrome and toxic epidermal necrolysis in the United States.

Authors:  Derek Y Hsu; Joaquin Brieva; Nanette B Silverberg; Amy S Paller; Jonathan I Silverberg
Journal:  J Am Acad Dermatol       Date:  2017-03-09       Impact factor: 11.527

4.  Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis and Treatment With a Biologic: A Case Report.

Authors:  Ian Chong; Alice Chao
Journal:  Perm J       Date:  2017

5.  Outbreak of Mycoplasma pneumoniae-Associated Stevens-Johnson Syndrome.

Authors:  Daniel Olson; Louise K Francois Watkins; Alicia Demirjian; Xia Lin; Christine C Robinson; Kristin Pretty; Alvaro J Benitez; Jonas M Winchell; Maureen H Diaz; Lisa A Miller; Teresa A Foo; Melanie D Mason; Ursula L Lauper; Oren Kupfer; Jeffrey Kennedy; Mary P Glodé; Preeta K Kutty; Samuel R Dominguez
Journal:  Pediatrics       Date:  2015-08       Impact factor: 7.124

Review 6.  Cutaneous drug reactions in children: an update.

Authors:  Kara Heelan; Neil H Shear
Journal:  Paediatr Drugs       Date:  2013-12       Impact factor: 3.022

7.  A comprehensive intervention for adverse drug reactions identification and reporting in a Pediatric Emergency Department.

Authors:  Olga Morales Ríos; Luis Jasso Gutiérrez; Juan O Talavera; Martha María Téllez-Rojo; Víctor Olivar López; Juan Garduño Espinosa; Onofre Muñoz Hernández
Journal:  Int J Clin Pharm       Date:  2016-02

Review 8.  SJS/TEN 2017: Building Multidisciplinary Networks to Drive Science and Translation.

Authors:  Katie D White; Riichiro Abe; Michael Ardern-Jones; Thomas Beachkofsky; Charles Bouchard; Bruce Carleton; James Chodosh; Ricardo Cibotti; Robert Davis; Joshua C Denny; Roni P Dodiuk-Gad; Elizabeth N Ergen; Jennifer L Goldman; James H Holmes; Shuen-Iu Hung; Mario E Lacouture; Rannakoe J Lehloenya; Simon Mallal; Teri A Manolio; Robert G Micheletti; Caroline M Mitchell; Maja Mockenhaupt; David A Ostrov; Rebecca Pavlos; Munir Pirmohamed; Elena Pope; Alec Redwood; Misha Rosenbach; Michael D Rosenblum; Jean-Claude Roujeau; Arturo P Saavedra; Hajirah N Saeed; Jeffery P Struewing; Hirohiko Sueki; Chonlaphat Sukasem; Cynthia Sung; Jason A Trubiano; Jessica Weintraub; Lisa M Wheatley; Kristina B Williams; Brandon Worley; Wen-Hung Chung; Neil H Shear; Elizabeth J Phillips
Journal:  J Allergy Clin Immunol Pract       Date:  2018 Jan - Feb

Review 9.  Applications of Immunopharmacogenomics: Predicting, Preventing, and Understanding Immune-Mediated Adverse Drug Reactions.

Authors:  Jason H Karnes; Matthew A Miller; Katie D White; Katherine C Konvinse; Rebecca K Pavlos; Alec J Redwood; Jonathan G Peter; Rannakoe Lehloenya; Simon A Mallal; Elizabeth J Phillips
Journal:  Annu Rev Pharmacol Toxicol       Date:  2018-08-22       Impact factor: 13.820

Review 10.  Severe Delayed Drug Reactions: Role of Genetics and Viral Infections.

Authors:  Rebecca Pavlos; Katie D White; Celestine Wanjalla; Simon A Mallal; Elizabeth J Phillips
Journal:  Immunol Allergy Clin North Am       Date:  2017-11       Impact factor: 3.479

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.